Paving the Way for a Novel PAH Treatment: A Collaborative Effort
Pulmonary arterial hypertension (PAH) is a life-threatening disease that predominantly affects women, progressively causing damage to the pulmonary vessels, leading to heart failure. Current treatments are limited, offering only symptomatic relief without addressing the underlying disease. However, a breakthrough is on the horizon, thanks to a multidisciplinary team from Monash University, including the Australian Translational […]
Australian Translational Medicinal Chemistry Facility
The Australian Translational Medicinal Chemistry Facility (ATMCF) is a purpose-designed and outward-facing collaborative facility, translating new discoveries in disease biology into suitably targeted therapeutics for clinical development. ATMCF partners with suitable researchers and companies to efficiently and effectively address the multifaceted requirements of drug-discovery. Read more about ATMCF here
